http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
White, H,Deprez, L,Corbisier, P,Hall, V,Lin, F,Mazoua, S,Trapmann, S,Aggerholm, A,Andrikovics, H,Akiki, S,Barbany, G,Boeckx, N,Bench, A,Catherwood, M,Cayuela, J-M,Chudleigh, S,Clench, T,Colomer, D,Dar Nature Publishing Group 2015 Leukemia Vol.29 No.2
<P>Serial quantification of <I>BCR–ABL1</I> mRNA is an important therapeutic indicator in chronic myeloid leukaemia, but there is a substantial variation in results reported by different laboratories. To improve comparability, an internationally accepted plasmid certified reference material (CRM) was developed according to ISO Guide 34:2009. Fragments of <I>BCR–ABL1</I> (e14a2 mRNA fusion)<I>, BCR</I> and <I>GUSB</I> transcripts were amplified and cloned into pUC18 to yield plasmid pIRMM0099. Six different linearised plasmid solutions were produced with the following copy number concentrations, assigned by digital PCR, and expanded uncertainties: 1.08±0.13 × 10<SUP>6</SUP>, 1.08±0.11 × 10<SUP>5</SUP>, 1.03±0.10 × 10<SUP>4</SUP>, 1.02±0.09 × 10<SUP>3</SUP>, 1.04±0.10 × 10<SUP>2</SUP> and 10.0±1.5 copies/μl. The certification of the material for the number of specific DNA fragments per plasmid, copy number concentration of the plasmid solutions and the assessment of inter-unit heterogeneity and stability were performed according to ISO Guide 35:2006. Two suitability studies performed by 63 <I>BCR–ABL1</I> testing laboratories demonstrated that this set of 6 plasmid CRMs can help to standardise a number of measured transcripts of e14a2 <I>BCR–ABL1</I> and three control genes (<I>ABL1, BCR</I> and <I>GUSB</I>). The set of six plasmid CRMs is distributed worldwide by the Institute for Reference Materials and Measurements (Belgium) and its authorised distributors (https://ec.europa.eu/jrc/en/reference-materials/catalogue/; CRM code ERM-AD623a-f).</P>
Tests of a dual-readout fiber calorimeter with SiPM light sensors
Antonello, M.,Caccia, M.,Cascella, M.,Dunser, M.,Ferrari, R.,Franchino, S.,Gaudio, G.,Hall, K.,Hauptman, J.,Jo, H.,Kang, K.,Kim, B.,Lee, S.,Lerner, G.,Pezzotti, L.,Santoro, R.,Vivarelli, I.,Ye, R.,Wig Elsevier 2018 Nuclear Instruments & Methods in Physics Research. Vol.899 No.-
<P><B>Abstract</B></P> <P>In this paper, we describe the first tests of a dual-readout fiber calorimeter in which silicon photomultipliers are used to sense the (scintillation and Čerenkov) light signals. The main challenge in this detector is implementing a design that minimizes the optical crosstalk between the two types of fibers, which are located very close to each other and carry light signals that differ in intensity by about a factor of 60. The experimental data, which were obtained with beams of high-energy electrons and muons as well as in lab tests, illustrate to what extent this challenge was met. The Čerenkov light yield, a limiting factor for the energy resolution of this type of calorimeter, was measured to be about twice that of the previously tested configurations based on photomultiplier tubes. The lateral profiles of electromagnetic showers were measured on a scale of millimeters from the shower axis and significant differences were found between the profiles measured with the scintillating and the Čerenkov fibers.</P>
Rings and gaps in the disc around Elias 24 revealed by ALMA
Dipierro, G,Ricci, L,Pé,rez, L,Lodato, G,Alexander, R D,Laibe, G,Andrews, S,Carpenter, J M,Chandler, C J,Greaves, J A,Hall, C,Henning, T,Kwon, W,Linz, H,Mundy, L,Sargent, A,Tazzari, M,Testi, L,W Oxford University Press 2018 Monthly notices of the Royal Astronomical Society Vol.475 No.4
Applications of Photonuclear Physics for International Safeguards and Security
M. S. Johnson,J. M. Hall,D. P. McNabb,J. L. McFarland,E. B. Norman,W. Bertozzi,S. E. Korbly,R. J. Ledoux,W. H. Park 한국물리학회 2011 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.59 No.23
Studies of nuclear resonance fluorescence based applications are presented. Important for these applications are data for isotopes such as ^(239)Pu. Nuclear resonance fluorescence measurements of ^(239)Pu were performed at the free electron laser facility at UC Santa Barbara using photons from a bremsstrahlung beam with an endpoint energies between 4.0 MeV and 5.5 MeV. Though no discrete states with significant confidence level were measured, we have excluded the region above 27(3) eV-barns, or 4-sigma, where we would expect only a small chance of false positives. Details of the measurements and the results are presented here.
The evolution of the Human Systems and Simulation Laboratory in nuclear power research
Hall Anna,Joe Jeffrey C.,Miyake Tina M.,Boring Ronald L. 한국원자력학회 2023 Nuclear Engineering and Technology Vol.55 No.3
The events at Three Mile Island in the United States brought about fundamental changes in the ways that simulation would be used in nuclear operations. The need for research simulators was identified to scientifically study human-centered risk and make recommendations for process control system designs. This paper documents the human factors research conducted at the Human Systems and Simulation Laboratory (HSSL) since its inception in 2010 at Idaho National Laboratory. The facility’s primary purposes are to provide support to utilities for system upgrades and to validate modernized control room concepts. In the last decade, however, as nuclear industry needs have evolved, so too have the purposes of the HSSL. Thus, beyond control room modernization, human factors researchers have evaluated the security of nuclear infrastructure from cyber adversaries and evaluated human-in-the-loop simulations for joint operations with an integrated hydrogen generation plant. Lastly, our review presents research using human reliability analysis techniques with data collected from HSSL-based studies and concludes with potential future directions for the HSSL, including severe accident management and advanced control room technologies
Sensitivity of the Advanced LIGO detectors at the beginning of gravitational wave astronomy
Martynov, D. V.,Hall, E. D.,Abbott, B. P.,Abbott, R.,Abbott, T. D.,Adams, C.,Adhikari, R. X.,Anderson, R. A.,Anderson, S. B.,Arai, K.,Arain, M. A.,Aston, S. M.,Austin, L.,Ballmer, S. W.,Barbet, M.,Bar American Physical Society 2016 Physical Review D Vol.93 No.11
Keystone, E C,Genovese, M C,Klareskog, L,Hsia, E C,Hall, S T,Miranda, P C,Pazdur, J,Bae, S-C,Palmer, W,Zrubek, J,Wiekowski, M,Visvanathan, S,Wu, Z,Rahman, M U BMJ Publishing Group 2009 Annals of the Rheumatic Diseases Vol.68 No.6
<P><B>Objective:</B></P><P>The phase III GO-FORWARD study examined the efficacy and safety of golimumab in patients with active rheumatoid arthritis (RA) despite methotrexate therapy.</P><P><B>Methods:</B></P><P>Patients were randomly assigned in a 3 : 3 : 2 : 2 ratio to receive placebo injections plus methotrexate capsules (group 1, n = 133), golimumab 100 mg injections plus placebo capsules (group 2, n = 133), golimumab 50 mg injections plus methotrexate capsules (group 3, n = 89), or golimumab 100 mg injections plus methotrexate capsules (group 4, n = 89). Injections were administered subcutaneously every 4 weeks. The co-primary endpoints were the proportion of patients with 20% or greater improvement in the American College of Rheumatology criteria (ACR20) at week 14 and the change from baseline in the health assessment questionnaire-disability index (HAQ-DI) score at week 24.</P><P><B>Results:</B></P><P>The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p = 0.059) in the golimumab 100 mg plus placebo group, 55.1% (p = 0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group. At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p = 0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively. During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients and serious infections occurred in 0.8%, 0.8%, 2.2% and 5.6%, respectively.</P><P><B>Conclusion:</B></P><P>The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function.</P>